Quest Diagnostics And CDC Expand Public Health Research Collaboration To Better Understand Hepatitis C Burden In The United States
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics (NYSE:DGX) has been awarded a multi-year contract by the CDC to assess the hepatitis C virus burden in the U.S. This marks a new phase in a decade-long collaboration, where Quest will provide research consulting, laboratory testing, and data analytics services. The project involves HCV antibody and molecular RNA testing on HIPAA-de-identified 'remnant' specimens. The collaboration aims to inform public policy and improve care for individuals with hepatitis C. Quest's extensive experience in hepatitis testing and its large database of de-identified laboratory results will support this initiative.
December 07, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics has secured a multi-year contract with the CDC for hepatitis C research, which could enhance its reputation as a leader in diagnostic services and potentially increase demand for its testing services.
The contract with the CDC is likely to have a positive short-term impact on Quest Diagnostics' stock price. The partnership not only reinforces Quest's position as a leading diagnostic service provider but also may lead to increased utilization of its testing services. The news reflects positively on the company's capabilities and commitment to public health, which could attract investor interest and potentially lead to an uptick in stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90